Welcome

Modern mass spectrometry developments hold significant potential for the discovery and sensitive detection of innovative (sets of) biomarkers which will allow rapid and accurate diagnosis of multiple disorders simultaneously in a single patient’s small-volume sample.

ProteoFormiX is running a mass spectrometry-based top-down proteomics technology platform to identify such disease-associated proteoforms (e.g., peptides) in clinically sampled human body fluids and tissues.

founder

ProteoFormiX was founded by Prof. Dr. Peter Verhaert in 2017. The company resides at JLINX, the European Johnson & Johnson Innovation Center.

company profile

menu

About ProteoFormiX

Projects & Services

Presence at International Scientific Meetings

Scientific Advisory Board

In the Media

Contact

Advertisements